Format

Send to

Choose Destination
J Pediatr. 1994 Jun;124(6):869-74.

Childhood vaccination against chickenpox: an analysis of benefits and costs.

Author information

1
Policy Analysis Inc., Brookline Massachusetts 02146.

Abstract

OBJECTIVE:

To estimate the economic costs and benefits of routine childhood vaccination against varicella infection.

DESIGN:

Decision-analytic model of the incidence and costs of chickenpox in children assumed to receive varicella vaccine at age 15 months in conjunction with the measles-mumps-rubella vaccine, or not to be vaccinated against varicella.

PATIENTS:

Hypothetical cohort of 100,000 children.

MAIN OUTCOME MEASURES:

Costs of vaccination, cumulative incidence of chickenpox to age 25 years, and related disease costs, including medical treatment and work loss.

RESULTS:

Vaccination of 100,000 children against varicella at age 15 months would cost $4,812,000. The expected number of cases of chickenpox to age 25 years would be reduced from 95,400 to 4800; costs of medical treatment and work loss would correspondingly decline by $1,678,000 and $9,781,000, respectively. On balance, vaccination is estimated to yield net economic benefits of $6,647,000, or $66.47 per vaccinee.

CONCLUSION:

Vaccination against varicella infection is cost-effective and should be part of the routine immunization schedule for U.S. children.

PMID:
8201469
DOI:
10.1016/s0022-3476(05)83173-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center